ChemComm
Communication
Funding for this work was from the University of Waterloo,
the Canadian Foundation for Innovation, the Natural Sciences
and Engineering Research Council (NSERC) of Canada and the
Early Researcher Award from Ontario MRI.
Notes and references
1 Y. W. Jung and S. J. Lippard, Chem. Rev., 2007, 107, 1387.
2 T. Boulikas and M. Vougiouka, Oncol. Rep., 2003, 10, 1663.
3 X. Y. Wang and Z. J. Guo, Dalton Trans., 2008, 1521.
4 B. Rosenberg, L. Vancamp, J. E. Trosko and V. H. Mansour, Nature,
1969, 222, 385.
5 D. Gibson, Dalton Trans., 2009, 10681.
6 P. M. Takahara, A. C. Rosenzweig, C. A. Frederick and S. J. Lippard,
Nature, 1995, 377, 649.
7 M. D. Hall, M. Okabe, D.-W. Shen, X.-J. Liang and M. M. Gottesman,
Annu. Rev. Pharmacol. Toxicol., 2008, 48, 495.
8 P. A. Andrews and S. B. Howell, Cancer Cell-Mon. Rev., 1990, 2, 35.
9 Q. B. Lu, S. Kalantari and C. R. Wang, Mol. Pharmaceutics, 2007,
4, 624.
10 D. B. Zamble, D. Mu, J. T. Reardon, A. Sancar and S. J. Lippard,
Biochemistry, 1996, 35, 10004.
11 A. Nemirovski, Y. Kasherman, Y. Tzaraf and D. Gibson, J. Med.
Chem., 2007, 50, 5554.
12 A. J. Zelazowski, J. S. Garvey and J. D. Hoeschele, Arch. Biochem.
Biophys., 1984, 229, 246.
13 C. Li, Z. Li, E. Sletten, F. Arnesano, M. Losacco, G. Natile and Y. Liu,
Angew. Chem., Int. Ed., 2009, 48, 8497.
14 T. Ishikawa and F. Ali-Osman, J. Biol. Chem., 1993, 268, 20116.
15 M. Knipp, A. V. Karotki, S. Chesnov, G. Natile, P. J. Sadler, V. Brabec
and M. Vasak, J. Med. Chem., 2007, 50, 4075.
16 R. C. Todd, K. S. Lovejoy and S. J. Lippard, J. Am. Chem. Soc., 2007,
129, 6370.
Fig. 3 (A) Inhibition of cisplatin binding to AF-A15 as a function of pH in citrate.
(B) Reaction of platinum-based compounds with AF-A15 in the presence or absence
of 10 mM citrate (denoted by the ‘+’ and ‘À’ signs). For all the gels, the first lane on
the left is the free DNA without cisplatin. (C) Structures of the platinum drugs and
citrate. Mixture of AF-A15 and FAM-G15 with cisplatin imaged with the AF channel
(D, G), the FAM channel (E, H) and the merged (F, I) in the absence of citrate (D–F)
or in the presence of 10 mM citrate (G–I) as a function of time.
17 J. Reedijk, Chem. Rev., 1999, 99, 2499.
18 E. Segal and J.-B. Le Pecq, Cancer Res., 1985, 45, 492.
19 J.-S. Park, S. H. Kim, N.-K. Lee, K. J. Lee and S.-C. Hong, Phys. Chem.
Chem. Phys., 2012, 14, 3128.
20 A. Ciancetta, C. Coletti, A. Marrone and N. Re, Dalton Trans., 2012,
41, 12960.
21 R. S. Sorokanich, A. J. Di Pasqua, M. Geier and J. C. Dabrowiak,
Chem. Biodiversity, 2008, 5, 1540.
22 W. Burgstaller, Microbiology, 2006, 152, 887.
The abovementioned studies mainly used A15 DNA since it
forms discrete bands in gels while the G15 products smeared
more. It needs to be noted that the inhibition effect is less
significant for G15 (Fig. S5, ESI†). An important advantage of
fluorescence is multiplexed detection. With two different fluoro- 23 J. Swiegers, I. Pretorius and F. Bauer, Curr. Genet., 2006, 50, 161.
24 D. E. Bauer, G. Hatzivassiliou, F. Zhao, C. Andreadis and
C. B. Thompson, Oncogene, 2005, 24, 6314.
25 L. Costello and R. Franklin, Mol. Cancer. Ther., 2006, 5, 17.
phores, we next tested the effect of citrate on reaction selectivity
between adenine and guanine. In the absence of citrate, both
FAM-G15 and AF-A15 reacted and the mobility decreased with time 26 A. Usenik and M. Legisa, PLoS One, 2010, 5, e15447.
27 K. Cullen, Z. Yang, L. Schumaker and Z. Guo, J. Bioenerg. Biomembr.,
(Fig. 3D–F). In the presence of citrate, AF-A15 was completely
inhibited as expected (Fig. 3G), while FAM-G15 still reacted
2007, 39, 43.
28 S. F. Bellon and S. J. Lippard, Biophys. Chem., 1990, 35, 179.
˜
(Fig. 3H), although slower than that in the absence of citrate. 29 F. Gonnet, F. Reeder, J. A. Kozelka and J.-C. Chottard, Inorg. Chem.,
1996, 35, 1653.
The merged band changed from orange to red after 4 h (Fig. 3I),
suggesting platination of FAM-G15. Therefore, an interesting role
30 S. K. C. Elmroth and S. J. Lippard, J. Am. Chem. Soc., 1994, 116, 3633.
31 M. Treskes, J. D. Jong, O. R. Leeuwenkamp and W. J. F. Van Der
of citrate is to increase the selectivity of cisplatin towards guanine
compared to adenine, which might have implications for guanine
being the eventual target of cisplatin.37–39
Vijgh, J. Liq. Chromatogr. Relat. Technol., 1990, 13, 1321.
32 T. Peleg-Shulman and D. Gibson, J. Am. Chem. Soc., 2001, 123, 3171.
33 M. E. Bosch, A. J. R. Sanchez, F. S. Rojas and C. B. Ojeda, J. Pharm.
Biomed. Anal., 2008, 47, 451.
In summary, we have employed fluorescently-labeled oligo- 34 J. F. Hartwig and S. J. Lippard, J. Am. Chem. Soc., 1992, 114, 5646.
35 E. R. Jamieson, M. P. Jacobson, C. M. Barnes, C. S. Chow and
S. J. Lippard, J. Biol. Chem., 1999, 274, 12346.
36 I. Tannock, Cancer Metastasis Rev., 2001, 20, 123.
nucleotides for studying the reaction between cisplatin and
DNA. Important reaction information such as product distribu-
tion, kinetics, and stoichiometry can all be obtained using this 37 K. J. Barnham, M. I. Djuran, P. del Socorro Murdoch and P. J. Sadler,
J. Chem. Soc., Chem. Commun., 1994, 721.
38 L. Rao and U. Bierbach, J. Am. Chem. Soc., 2007, 129, 15764.
39 M.-H. Baik, R. A. Friesner and S. J. Lippard, J. Am. Chem. Soc., 2003,
simple method. We further showed that citrate is an inhibitor
for this reaction but can increase selectivity toward guanine
over adenine.
125, 14082.
c
This journal is The Royal Society of Chemistry 2013
9484 Chem. Commun., 2013, 49, 9482--9484